Please assess the completion status of the following clinical trial:

Trial Title: Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperuricemia (serum uric acid ≥8.0 mg/dL).~* Must meet American College of Rheumatology criteria for gout.~* Must have adequate renal function (serum creatinine \<1.5 mg/dL).~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~Exclusion Criteria:~* History of xanthinuria~* Alcohol consumption \>14/week~* Has a history of significant concomitant illness.~* Has active liver disease.~* Has a body mass index greater than 50 kilogram per meter² (kg/m²)~* Any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo QD (Type: PLACEBO_COMPARATOR): None
- Febuxostat 40 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 120 mg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).